Marker Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
MRKR$0.95-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the Years Ended | ||||||
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Cash Flows from Operating Activities: | | | | | | |
| Net loss | | $(12,163,620) | | $(10,731,315) | ||
| Reconciliation of net loss to net cash used in operating activities: | | | | | ||
| Stock-based compensation | | 537,540 | | 245,864 | ||
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and deposits | | (175,033) | | 504,409 | ||
| Other receivables | | 977,303 | | (1,318,888) | ||
| Related party payable | | | (1,710,500) | | | 380,845 |
| Accounts payable and accrued expenses | | (454,570) | | 8,761 | ||
| Deferred revenue | | | 974,799 | | | — |
| Net cash used in operating activities | | (12,014,081) | | (10,910,324) | ||
| Cash Flows from Financing Activities: | | | | | ||
| Proceeds from issuance of common stock, net | | 9,863,883 | | 14,929,155 | ||
| Proceeds from exercise of warrants and stock options | | 605 | | 62,159 | ||
| Net cash provided by financing activities | | 9,864,488 | | 14,991,314 | ||
| Net (decrease) increase in cash, cash equivalents, and restricted cash | | (2,149,593) | | 4,080,990 | ||
| Cash, cash equivalents, and restricted cash at beginning of the year | | 19,192,440 | | 15,111,450 | ||
| Cash, cash equivalents, and restricted cash at end of the year | | $17,042,847 | | $19,192,440 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.